Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,65 USD | -0,38% | 0,00% | +11,81% |
01/03 | Kinnate Biopharma verkoopt kankerbehandelingsactiva aan Pierre Fabre Laboratories | MT |
26/02 | KINNATE BIOPHARMA INC. : Stifel Nicolaus herhaalt Neutraal advies | ZM |
Omzet 2023 | - | Omzet 2024 * | - | Marktkapitalisatie | 126 mln. 116 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -113 mln. -105 mln. | Nettowinst (verlies) 2024 * | -62 mln. -57,48 mln. | EV/omzet 2023 | - |
Nettoliquiditeiten 2023 * | 163 mln. 151 mln. | Nettoliquiditeiten 2024 * | 109 mln. 101 mln. | EV/omzet 2024 * | - |
K/w-verhouding 2023 |
-0,98
x | K/w-verhouding 2024 * |
-2,07
x | Werknemers | 84 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 70,63% |
1 dag | -0,38% | ||
Lopende maand | +7,29% | ||
1 maand | +6,43% | ||
3 maanden | +8,61% | ||
6 maanden | +92,03% | ||
Lopend jaar | +11,81% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Nima Farzan
CEO | Chief Executive Officer | 48 | 01-03-20 |
Director of Finance/CFO | 37 | 07-06-21 | |
Quah Cheng
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dean Mitchell
CHM | Chairman | 68 | 09-09-20 |
James Tananbaum
BRD | Director/Board Member | 59 | 01-06-20 |
Carl Gordon
BRD | Director/Board Member | 59 | 01-12-19 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.02% | 0 M€ | 0,00% | - | |
0.01% | 0 M€ | 0,00% | - | |
0.00% | 2 M€ | -.--% | ||
0.00% | 8 M€ | +9,75% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 2,66 | 0,00% | 518 478 |
27-03-24 | 2,66 | +1,14% | 472 324 |
26-03-24 | 2,63 | -0,75% | 714 882 |
25-03-24 | 2,65 | 0,00% | 340 709 |
22-03-24 | 2,65 | 0,00% | 1 770 785 |
uitgestelde koers Nasdaq, 28 maart 2024 om 20:59 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,81% | 126 mln. | |
+9,30% | 46,03 mld. | |
+52,73% | 44,55 mld. | |
+7,15% | 40,8 mld. | |
-8,78% | 28,25 mld. | |
+18,68% | 27,71 mld. | |
-21,92% | 18,82 mld. | |
+14,62% | 13,91 mld. | |
+31,85% | 12,43 mld. | |
+4,47% | 10,81 mld. |